Efficacy and Safety Study of GB-0998 for Guillain-Barre Syndrome

Trial Profile

Efficacy and Safety Study of GB-0998 for Guillain-Barre Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Immunoglobulin G (Primary)
  • Indications Guillain-Barre syndrome
  • Focus Therapeutic Use
  • Sponsors Japan Blood Products Organization
  • Most Recent Events

    • 03 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 22 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top